###begin article-title 0
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 96 100 96 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
###end article-title 0
###begin p 1
Conceived and designed the experiments: IL RS CH AAGvT MK AH ECZ. Performed the experiments: IL RS. Analyzed the data: IL RS CH AAGvT MK AH ECZ. Contributed reagents/materials/analysis tools: RS CH AH. Wrote the paper: IL AAGvT MK AH ECZ.
###end p 1
###begin p 2
###xml 215 219 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 221 225 221 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 327 331 327 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 339 343 339 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 495 499 495 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 598 602 598 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 714 718 714 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 788 794 788 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 799 803 799 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 810 814 810 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 841 845 841 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 897 903 897 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 940 946 940 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 951 955 951 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 432 440 <span type="species:ncbi:9606">patients</span>
###xml 1492 1500 <span type="species:ncbi:9606">patients</span>
Recently a number of randomized trials have shown that patients with advanced colorectal cancer do not benefit from therapies targeting the epidermal growth factor receptor when their tumors harbor mutations in the KRAS, BRAF and PIK3CA genes. We developed two multiplex assays that simultaneously screen 22 nucleotides in the KRAS, NRAS, BRAF and PIK3CA genes for mutations. The assays were validated on 294 tumor DNA samples from patients with advanced colorectal cancer. In these samples 119 KRAS codon 12 and 13 mutations had been identified by sequence analysis, 126 tumors were wild-type for KRAS and the analysis failed in 49 of the 294 samples due to poor DNA quality. The two mutation assays detected 130 KRAS mutations, among which were 3 codon 61 mutations, and in addition 32 PIK3CA, 13 BRAF and 6 NRAS mutations. In 19 tumors a KRAS mutation was found together with a mutation in the PIK3CA gene. One tumor was mutant for both PIK3CA and BRAF. In summary, the mutations assays identified 161 tumors with a mutation, 120 were wild-type and the analysis failed in 13. The material cost of the 2 mutation assays was calculated to be 8-fold lower than the cost of sequencing required to obtain the same data. In addition, the mutation assays are less labor intensive. We conclude that the performance of the two multiplex mutation assays was superior to direct sequencing. In addition, these assays are cheaper and easier to interpret. The assays may also be of use for selection of patients with other tumor types.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 241 245 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 247 251 247 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 256 262 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 269 272 269 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Amado1">[1]</xref>
###xml 274 277 274 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Raponi1">[2]</xref>
###xml 279 282 279 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Siena1">[3]</xref>
###xml 298 302 298 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 426 430 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 657 661 657 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 666 672 666 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 773 776 773 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Siena1">[3]</xref>
###xml 778 781 778 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-SartoreBianchi1">[4]</xref>
###xml 783 786 783 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Benvenuti1">[5]</xref>
###xml 788 791 788 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-DiNicolantonio1">[6]</xref>
###xml 793 796 793 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-SartoreBianchi2">[7]</xref>
###xml 798 801 798 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Jhawer1">[8]</xref>
###xml 803 806 803 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Prenen1">[9]</xref>
###xml 808 812 808 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-LaurentPuig1">[10]</xref>
###xml 840 844 840 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 846 850 846 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 855 861 855 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 933 937 933 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Barault1">[11]</xref>
###xml 939 943 939 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Ogino1">[12]</xref>
###xml 972 976 972 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 1015 1019 1015 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1080 1088 1080 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The NRAS</italic>
###xml 1172 1176 1172 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
###xml 901 909 <span type="species:ncbi:9606">patients</span>
Recently a number of randomized trials have shown that treatment of patients with advanced colorectal cancer (CRC) do not benefit from therapies targeting the epidermal growth factor receptor (EGFR) when their tumors harbor mutations in the KRAS, BRAF and PIK3CA genes [1], [2], [3]. Consequently, KRAS mutation analysis is a prerequisite for anti-EGFR therapy in metastasized CRC and only patients with tumors that harbor no KRAS mutations receive this therapy (European Medicine Agency - EMEA-H-C-741 and H-C-558 and U.S. Food and Drug Administration - FDA Application No. (BLA) 125084 and No. (BLA) 125147). Recent publications suggest that mutations in BRAF and PIK3CA may also confer resistance to anti-EGFR therapy, although this is not entirely clear for PIK3CA yet [3], [4], [5], [6], [7], [8], [9], [10]. In addition, mutations in KRAS, BRAF and PIK3CA are associated with a worse outcome in patients with colorectal cancer [11], [12]. The protein encoded by the NRAS gene functions in the same pathway as KRAS and mutations in this gene have been found in 3% of CRC (). The NRAS gene is highly expressed in CRC (), hence it is to be expected that tumors with an NRAS mutations are resistant to EGFR targeted therapy.
###end p 4
###begin p 5
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-vanOers1">[13]</xref>
###xml 568 574 568 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 574 578 574 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Hurst1">[14]</xref>
###xml 697 701 697 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Burger1">[15]</xref>
###xml 703 707 703 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Hafner1">[16]</xref>
###xml 709 713 709 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Junker1">[17]</xref>
###xml 715 719 715 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-vanOers2">[18]</xref>
###xml 721 725 721 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Kompier1">[19]</xref>
###xml 731 736 731 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FGFR3</italic>
###xml 1000 1004 1000 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1006 1010 1006 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 1012 1016 1012 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1021 1027 1021 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1082 1086 1082 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1091 1095 1091 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1118 1124 1118 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1129 1133 1129 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 1236 1240 1236 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
The above findings suggest that mutation analysis for the KRAS, NRAS, BRAF and PIK3CA genes should be implemented in molecular diagnostic laboratories. Together these genes harbor 22 possible mutation sites distributed over 7 exons. Mutation analysis by sequencing therefore typically requires 7 individual PCR reactions followed by 14 bi-directional sequence reactions. We have previously developed a multiplex assay for the identification of 11 possible point mutations in the gene for the fibroblast growth factor receptor 3 (FGFR3) [13] and 4 hotspot mutations in PIK3CA[14]. These mutations are a common phenomenon in primary and recurrent urinary bladder carcinomas and various skin lesions [15], [16], [17], [18], [19]. The FGFR3 mutation assay needs little DNA, has a high performance rate on DNA isolated from formalin-fixed paraffin embedded tissue (FFPE DNA) and urine and was found to be highly reproducible. Bearing this in mind we set out to develop similar assays for mutations in the KRAS, NRAS, BRAF and PIK3CA genes. This resulted in two multiplex assays, one for BRAF and KRAS mutations and one for PIK3CA and NRAS. The performance of the assays was tested on 294 CRC samples that had been sequenced for mutations in KRAS exon 2 and was found to be superior to sequencing.
###end p 5
###begin title 6
Materials and Methods
###end title 6
###begin title 7
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient Characteristics and Ethics Statement
###end title 7
###begin p 8
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 311 323 <span type="species:ncbi:9606">participants</span>
The samples used in the presented study were taken from a consecutive series of metastasized colon carcinoma cases analyzed for KRAS mutation status in the course of routine molecular pathological identification of applicable patients for anti-EGFR therapy at the Institute of Pathology, Erlangen, Germany. All participants for mutation analysis gave written informed consent via the treating physician. Ethical approval for the retrospective use of paraffin material for the study was given by the ethical committee of the University Erlangen.
###end p 8
###begin title 9
DNA Isolation and Sequence Analysis
###end title 9
###begin p 10
###xml 440 444 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 498 502 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Feng1">[20]</xref>
Tumor tissue was marked on a hematoxylin-eosin-stained tissue section by an experienced surgical pathologist (AH). After deparaffinization and rehydration tumor cells were carefully microdissected manually from serial sections. DNA was isolated using the QIAamp(R) DNA FFPE Tissue Kit (QIAGEN, Hilden, Germany). Quantity and quality of the DNA were controlled using a spectral photometer (NanoDrop(R), peQLab, Erlangen, Germany). Exon 2 of KRAS was amplified using PCR primers published previously [20] and the QIAGEN(R) Multiplex PCR Kit using 150-200 ng DNA. PCR cycles were as follows: 94degreesC for 5 min, 35 cycles of 94degreesC for 1 min, 60degreesC for 1 min, 72degreesC for 1 min, followed by an elongation step at 72degreesC for 10 min. Sequence analysis in both directions was performed using PCR primers and the Big Dye(R) Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA). Products from sequence reaction were purified using the DyeEx(R) 2.0 Spin Kit (QIAGEN, Hilden, Germany) and analysed by capillary electrophoresis (ABI PRISM(R) 310 Genetic Analyzer, Applied Biosystems, Foster City, CA, USA). DNA from cell line HCT116 (obtained from ATCC, Middlesex, United Kingdom) containing a heterozygous G13D mutation was used as a control for each analysis.
###end p 10
###begin title 11
Mutation Assays
###end title 11
###begin p 12
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Hurst1">[14]</xref>
###xml 492 500 492 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008802.s001">Table S1</xref>
###xml 2283 2291 2205 2213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008802.s002">Table S2</xref>
Two multiplex PCRs were designed, the first for BRAF exon 15 and KRAS exons 2 and 3 and the second for PIK3CA exons 9 and 20 and NRAS exons 2 and 3. The primers were chosen in such a way that the single strands of the PCR products contained as little potential secondary structure as possible in order to facilitate efficient annealing of the mutation detection probes. Primers and probes for PIK3CA were derived from Hurst [14]. Primer sequences for multiplex PCR are given in Supplementary Table S1. The multiplex PCR was performed in a total volume of 15 microl, containing 1x PCR buffer, 1.5 mM MgCl2, 0.5 units Go-Taq DNA polymerase (Promega, Madison, WI), 0.17 mM dNTP's (Roche, Basel, Switzerland), 0.3-1 microM primers (Invitrogen, Carlsbad, CA), 5% glycerol (Fluka, Buchs SG, Switzerland) and 5 ng genomic DNA. Thermal cycling conditions were: 5 minutes at 95degreesC, 35 cycles at 95degreesC for 45 seconds, 55degreesC for 45 seconds and 72degreesC for 45 seconds, followed by 10 minutes at 72degreesC. The PCR products were treated with 2 units Exonuclease I (ExoI) and 3 units Shrimp Alkaline Phosphatase (SAP) (USB, Cleveland, Ohio USA). This was followed by a single nucleotide probe extension assay using a SNaPshot Multiplex kit (Applied Biosystems, Foster City, CA) and probes designed to anneal to either the forward or the reverse strand of a PCR product adjacent to the mutation site of interest. These probes were fitted with T tails of different length at their 5'ends to allow separation of the extension products by size. The mutation detection reactions were performed in a total volume of 10 microl, containing 1 microl SAP/ExoI treated PCR product, 2.5 microl SNaPshot Multiplex Ready Reaction mix, 1 x Big Dye sequencing buffer and 1 microl probe mix. Thermal cycler conditions were: 35 cycles of 10 seconds at 96degreesC and 40 seconds at 58.5degreesC. The products were treated with 1 unit SAP at 37degreesC for 60 min and 72degreesC for 15 min and analyzed on an automatic sequencer (ABI PRISM 3130 XL Genetic Analyzer, Applied Biosystems) with the fluorescent label on the incorporated ddNTP indicating the presence or absence of a mutation. For analysis of the data Genescan Analysis Software version 3.7 (Applied Biosystems) was used. Supplementary Table S2 gives an overview of the probes used and indicates the peak color that correlates with each mutation. Contamination may occur when lifting the cover of the PCR plate after PCR and when material from the PCR reaction is transferred to another well for sequencing or for the mutation assay. This risk is the same for sequencing and the mutation assays. Contamination will result in relatively small mutant peaks because only a fraction of the PCR reaction will have been transferred to another well. Because of this, we usually independently verify a mutation when the mutant peak is lower than 10% of the wild type peak.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
Mutation Detection Assays
###end title 14
###begin p 15
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 35 43 35 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008802-g001">Figure 1</xref>
###xml 667 676 667 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAS/KRAS</italic>
###xml 770 778 770 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008802-g002">Figure 2</xref>
###xml 791 797 791 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 798 802 798 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
The BRAF/KRAS assay is depicted in Figure 1 with the interrogated codons and nucleotides shown at the bottom. The colors of the peaks indicate the nature of the specific dideoxynucleotide that was added to the mutation detection probe. The top panel is a wild type control and the three other panels show examples of mutations. When a mutation is present a different dideoxynucleotide is incorporated resulting in a peak of a different color. Because the type of fluorescent label influences separation through the polymer, mutant and wild type extension products usually migrate to slightly different positions, further facilitating identification of mutations. The BRAS/KRAS assay simultaneously interrogates 10 nucleotides in 3 exons for 22 possible point mutations. Figure 2 depicts the PIK3CA/NRAS assay for wild type control DNA and 3 samples containing mutations. This assay is able to detect 25 possible mutations in 12 nucleotides in 4 exons.
###end p 15
###begin title 16
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Assay for BRAF and KRAS mutations.
###end title 16
###begin p 17
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Panel A: wild-type control. Panels B-D: examples of BRAF and KRAS mutations. Positions of codons and nucleotides are indicated at the bottom of the figure.
###end p 17
###begin title 18
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
Assay for PIK3CA and NRAS mutations.
###end title 18
###begin p 19
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
Panel A: wild-type control. Panels B-D: examples of PIK3CA and NRAS mutations. Positions of codons and nucleotides are indicated at the bottom of the figure.
###end p 19
###begin title 20
Validation of the Assays
###end title 20
###begin p 21
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 467 471 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 472 476 472 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 481 487 481 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 488 492 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 543 547 543 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 552 558 552 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 563 567 563 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 574 578 574 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 628 635 628 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0008802-t001">table 1</xref>
###xml 647 653 647 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 718 722 718 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 745 749 745 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 976 980 976 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1024 1033 1024 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF/KRAS</italic>
###xml 1519 1527 1519 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0008802-g003">Figure 3</xref>
###xml 1690 1698 1690 1698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008802.s003">Table S3</xref>
###xml 2348 2352 2348 2352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-vanOers1">[13]</xref>
###xml 2391 2395 2391 2395 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
To validate the assays we analyzed DNA samples isolated from 294 CRCs that had already been analyzed for mutations in exon 2 of the KRAS gene. In 281/294 (96%) of the samples the two mutation assays were successful in establishing a mutant or wild-type outcome. Mutations were identified in 161/281 (57%) of the cases and120 samples were wild-type (43%). We then we performed a second independent mutation analysis on all samples and observed that the results of the BRAF/KRAS and PIK3CA/NRAS assays were completely reproducible. We found 130 KRAS, 32 PIK3CA, 13 BRAF and 6 NRAS mutations. Details of the mutations are given in table 1. Of the 32 PIK3CA mutations 12 were single mutations, 19 occurred together with a KRAS mutation and 1 with a BRAF mutation. The mutation assays were performed in a blinded fashion and the results were compared afterwards with the results of the sequence analysis. There were 14 samples with discrepant results between sequence analysis for KRAS exon 2 (covering codons 12 and 13) and the BRAF/KRAS mutation assay. As the latter had already been confirmed by an independent assay, the 14 samples were resequenced. In 9 cases, the sequence outcome now appeared identical to the mutation assay result and in 4 cases sequencing was unsuccessful due to poor DNA quality. In the 1 remaining sample (no. 289) sequencing suggested wild-type whereas the mutation assay detected a G12V mutation with the mutant peak being 6% of the wild type peak, suggesting that the tumor was heterogeneous. Figure 3 depicts a concise overview of sequence and mutation assay results. A detailed overview of the results of sequencing and mutation assays is given in Supplementary Table S3. In this table we also included the relative peak height of the mutant peaks compared to the wild type peak as observed in the mutation assays. Note that this is at best semi-quantitative because of the different absorbances of the fluorescent labels, however, it gives an indication of the relative proportions of mutant and wild-type genes. Wild-type peaks in the assays have a height between 2000-8000. Peaks (mutant) with a peak height of 100 are always visible. Based on this we estimate that sensitivity is between 1-5%. This correlates well with the sensitivity calculated from dilution experiments in a similar assay as published previously [13]. Note that in some samples the mutant KRAS peaks were much higher than the peaks representing the wild type allele. We presume that this indicates loss of the wild-type allele.
###end p 21
###begin title 22
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Overview of the resultsobtained by the mutation assays (A) and by sequence analysis (B) in 294 tumor DNA samples from patients with advanced colorectal cancer.
###end title 22
###begin title 23
###xml 30 39 30 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF/KRAS</italic>
###xml 44 55 44 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA/NRAS</italic>
Mutations identified with the BRAF/KRAS and PIK3CA/NRAS assays.
###end title 23
###begin title 24
Costs Comparison
###end title 24
###begin p 25
###xml 193 199 193 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 210 214 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 523 531 517 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0008802.s004">Table S4</xref>
###xml 380 384 <span type="species:ncbi:9319">euro</span>
###xml 431 435 <span type="species:ncbi:9319">euro</span>
Next we compared the costs of both approaches. We observed mutations in all 4 genes, hence we assume that future mutation analysis, be it by sequencing or any other technique, will include the PIK3CA, NRAS and BRAF genes. We calculated the costs for all materials and reagents including those associated with the running of samples on the ABI 3130 XL sequencer. These amounted to euro 7.03 for the two mutation assays together and euro 59.54 for bi-directional sequencing of the 7 exons. Details are given in Supplementary Table S4. Personnel costs are also lower for the mutation assays compared to sequencing. This is because only 2 PCR reactions have to be performed compared to 7 for sequencing and only 2 electrophoresis runs need to be performed compared to 14 for sequence analysis. There is no need to buy other equipment than that required for sequence analysis. Any laboratory with PCR machines and a capillary sequencer can perform these assays. The cost comparison thus indicates that the mutation assays are less expensive than sequencing.
###end p 25
###begin title 26
Discussion
###end title 26
###begin p 27
###xml 481 485 481 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Hynes1">[21]</xref>
###xml 487 491 487 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 629 635 629 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 640 644 640 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 740 743 740 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Siena1">[3]</xref>
###xml 745 748 745 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-SartoreBianchi1">[4]</xref>
###xml 750 753 750 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-DiNicolantonio1">[6]</xref>
###xml 755 758 755 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-SartoreBianchi2">[7]</xref>
###xml 760 763 760 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Jhawer1">[8]</xref>
###xml 765 769 765 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Perrone1">[22]</xref>
###xml 771 775 771 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0008802-Souglakos1">[23]</xref>
###xml 826 830 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 966 970 966 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 1136 1140 1136 1140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1149 1155 1149 1155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1157 1161 1157 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1166 1170 1166 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 1254 1258 1254 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1260 1264 1260 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1266 1272 1266 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PIK3CA</italic>
###xml 1277 1281 1277 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 1329 1333 1329 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1661 1665 1661 1665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 708 715 <span type="species:ncbi:9606">patient</span>
###xml 795 803 <span type="species:ncbi:9606">patients</span>
###xml 1048 1056 <span type="species:ncbi:9606">patients</span>
###xml 1407 1415 <span type="species:ncbi:9606">patients</span>
###xml 1460 1468 <span type="species:ncbi:9606">patients</span>
###xml 1578 1586 <span type="species:ncbi:9606">patients</span>
###xml 1704 1712 <span type="species:ncbi:9606">patients</span>
The EGF receptor signals through the RAS-MAPK and PIK3 kinase pathways. Activating mutations in proteins that function downstream of the EGFR in these signal transduction pathways renders the cell independent of EGFR signaling. Hence inhibition of the receptor has no effect. Most other receptor tyrosine kinases employ the same signaling pathways and therefore the same mechanism is likely to apply to trastuzumab resistant breast cancer or gefitinib or erlotinib resistant NSCLC [21]. KRAS mutation analysis is now standard for selection of patients for EGFR targeted therapy. Recently, it has been shown that mutations in the PIK3CA and BRAF genes may also confer resistance to anti-EGFR therapy although patient numbers are still small [3], [4], [6], [7], [8], [22], [23]. It is likely that patients with tumors harboring NRAS mutations will also not benefit from anti-EGFR therapy, however, this remains to be proven which is also the case for mutations in the NRAS gene. Once this has been established, mutation analysis for the selection of patients for whom anti-EGFR therapy will be beneficial presumably has to be extended to KRAS exon 3, PIK3CA, BRAF and NRAS. Here we presented two simple assays that together screen 22 mutation sites in the KRAS, BRAF, PIK3CA and NRAS oncogenes. When we dismiss the failed samples, KRAS exon 2 mutations were found by sequence analysis in 119/245 (49%) of the patients, the mutation assays detected 161/281 (57%) patients with mutant tumors. This suggests that when both sequencing and mutation analysis are 100% successful, 8% of patients (57 minus 49) would receive anti-EGFR therapy in vain when only exon 2 of KRAS would have been assayed. In practice, patients with tumors in which the analysis failed will receive anti-EGFR therapy, suggesting that efficient mutation detection is important.
###end p 27
###begin p 28
###xml 221 225 221 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Identification of the mutations in the assays presented here is more straight forward than with sequencing and the results were completely reproducible. Sequence analysis failed in 17% of the samples. This was 4% for the KRAS mutation assay. The DNA samples used in our analyses were FFPE derived. It is known that FFPE derived DNA is not always of good quality and this was indeed the reason for the failed samples. In principle sequencing and the mutation assays are similar techniques. That the mutation assay is able to give a result in more samples than sequencing is probably because the fluorescent signals are distributed over fewer peaks. In cases with poor DNA quality, this is also immediately apparent from much lower or even missing peaks. Although not used in this work, it is possible to repeat the mutation assay with a single probe when one doubts the result, for instance when the presumed mutant peak is very small.
###end p 28
###begin p 29
For analysis of all the mutations by sequencing one would have to perform independent PCRs for the 7 exons, followed by 14 bi-directional sequencing reactions. In the mutation assays two multiplex PCRs for 3 and 4 exons, respectively, are followed by two multiplex detection assays and two electrophoresis runs on the sequencer. Besides being considerably cheaper (euro7 compared to euro60), less DNA is needed and the assays are less labor intensive.
###end p 29
###begin p 30
###xml 109 117 <span type="species:ncbi:9606">patients</span>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
We conclude that these assays provide a simple and inexpensive companion diagnostic for the selection of CRC patients for anti-EGFR therapy. The assays may also be of use for selection of patients with ERBB2 positive breast cancer or non-small cell lung cancer carrying EGFR mutations.
###end p 30
###begin title 31
Supporting Information
###end title 31
###begin p 32
Primer sequences for multiplex PCR.
###end p 32
###begin p 33
(0.02 MB XLS)
###end p 33
###begin p 34
Click here for additional data file.
###end p 34
###begin p 35
Overview of the probes used and indication of the peak color that correlates with each mutation.
###end p 35
###begin p 36
(0.02 MB XLS)
###end p 36
###begin p 37
Click here for additional data file.
###end p 37
###begin p 38
Detailed overview of the results of sequencing and mutation assays.
###end p 38
###begin p 39
(0.06 MB XLS)
###end p 39
###begin p 40
Click here for additional data file.
###end p 40
###begin p 41
Costs: Mutation Assays vs. Sequencing (Bi-directional).
###end p 41
###begin p 42
(0.02 MB XLS)
###end p 42
###begin p 43
Click here for additional data file.
###end p 43
###begin p 44
We thank Ms. Claudia Knoll and Ms. Andrea Kosel for excellent technical assistance.
###end p 44
###begin title 45
References
###end title 45
###begin article-title 46
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
###end article-title 46
###begin article-title 47
KRAS mutations predict response to EGFR inhibitors.
###end article-title 47
###begin article-title 48
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
###end article-title 48
###begin article-title 49
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
###end article-title 49
###begin article-title 50
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
###end article-title 50
###begin article-title 51
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
###end article-title 51
###begin article-title 52
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
###end article-title 52
###begin article-title 53
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.
###end article-title 53
###begin article-title 54
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
###end article-title 54
###begin article-title 55
Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
###end article-title 55
###begin article-title 56
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers.
###end article-title 56
###begin article-title 57
###xml 56 64 <span type="species:ncbi:9606">patients</span>
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.
###end article-title 57
###begin article-title 58
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
###end article-title 58
###begin article-title 59
A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene.
###end article-title 59
###begin article-title 60
Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
###end article-title 60
###begin article-title 61
###xml 43 48 <span type="species:ncbi:9606">human</span>
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.
###end article-title 61
###begin article-title 62
Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations.
###end article-title 62
###begin article-title 63
FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder Tumours.
###end article-title 63
###begin article-title 64
The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
###end article-title 64
###begin article-title 65
BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.
###end article-title 65
###begin article-title 66
ErbB receptors and signaling pathways in cancer.
###end article-title 66
###begin article-title 67
###xml 104 112 <span type="species:ncbi:9606">patients</span>
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.
###end article-title 67
###begin article-title 68
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
###end article-title 68
###begin p 69
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 69
###begin p 70
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by a research grant by the German Research Foundation (DFG) to AH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 70

